[Controversial aspects regarding metformin in type 2 diabetic patient: reduction of late complications in early, single drug administration; increased risk of death in later administration in combination with sulfonylurea compounds].
Ritzmann
P
P
Medizinische Poliklinik Universitätsspital, Zürich.
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000401:mortality; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000401:mortality; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D008687:Metformin / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D009765:Obesity; D012307:Risk Factors; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D015996:Survival Rate
D001786:Blood Glucose; D013453:Sulfonylurea Compounds; D008687:Metformin